SITE MAP   |   CONTACT US



Biovail Announces Third-Quarter 2009 Earnings Release, Conference-Call Details

TORONTO--(BUSINESS WIRE)--Oct. 23, 2009-- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that it will host a conference call and webcast on Thursday, November 5, 2009 at 8:30a.m. for Company executives to discuss third-quarter 2009 financial and operational results.

Following the discussion, Biovail executives will address inquiries from investment analysts.

A live webcast of this call will be available through the Investor Relations section of Biovail’s website at www.biovail.com. To access the call live, please dial 416-340-8427 (Toronto and International callers) and 1-866-225-2055 (U.S. and Canada). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00p.m. ET on Thursday, November 12, 2009 by dialing 416-695-5800 (Toronto and International callers) and 1-800-408-3053 (U.S. and Canada), using access code: 2777843#.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company’s Web site at www.biovail.com.

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com.

Source: Biovail Corporation

Biovail Corporation
Nelson F. Isabel, (905) 286-3000
Vice-President, Investor Relations & Corporate Communications

Tools

Investment Calculator


Email Alerts

Resources

Q2 2010 Financial Results

Valeant - Biovail Analyst Investor Presentation

Biovail - Valeant Merger Conference Call

Biovail's Product Pipeline

Pimavanserin Schizophrenia Co-Therapy - Phase 2 Data

Aplenzin Prescribing Information

Nitoman Prescribing Information

Xenazine Prescribing Information

Xenazine Medication Guide

Corporate Fact Sheet

IMPORTANT: Income Tax Information for Canadian Resident Shareholders


Download Adobe Acrobat Reader

Events




© 2007 Biovail Corporation - All Rights Reserved (BIO113B0602) Privacy Policy   |   Disclaimers